Pink Sheet Podcast: Affordability And The US Coronavirus Response, Biologics Transition Guidance May Force Strategy Changes
Executive Summary
Pink Sheet reporter and editor consider congressional demands that government-funded coronavirus research produce affordable medicines and vaccines, as well as the one-word change to the biologics transition guidance that may affect the availability of authorized biosimilars.